Treatment for advanced hepatocellular carcinoma by transarterial chemotherapy using reservoirs or one-shot arterial chemotherapy.
Treatment for advanced hepatocellular carcinoma by transarterial chemotherapy using reservoirs or one-shot arterial chemotherapy.
复制标题
通过使用储库的经动脉化疗或一次性动脉化疗治疗晚期肝细胞癌。
DOI：
10.1179/joc.1997.9.5.347
复制
发表时间：
1997
影响因子：
1.8
通讯作者：
C. Sato
中科院分区：
文献类型：
--
作者：
Y. Sakai;N. Izumi;J. Tazawa;T. Yoshida;H. Sakai;T. Yauchi;K. Hattori;S. Tozuka;F. Marumo;C. Sato
在晚期肝细胞癌患者中进行了一项前瞻性试验，以评估使用植入式储药器的经导管动脉化疗（12例患者）或常规经导管动脉化疗（8例患者）的治疗效果。前者每月给予40 mg/m2的依匹鲁胺，后者每3个月给予60 mg/m2的依匹鲁胺。在6个月内，储库组的住院时间和总住院费用均低于常规化疗组（分别为p < 0.05和p < 0.01）。使用植入式储药器的经导管动脉化疗可以在日间护理的基础上进行，并且可能有益于晚期肝细胞癌患者的治疗。
A prospective trial was performed in patients with advanced hepatocellular carcinoma to assess the therapeutic efficacy of transcatheter arterial chemotherapy using implanted reservoirs (12 patients) or conventional transcatheter arterial chemotherapy (8 patients). Epirubicin at a dose of 40 mg/m2 was given every month in the former, while epirubicin at a dose of 60 mg/m2 was administered every 3 months in the latter. During the 6 months from the introduction of these therapies, hospitalized periods were shorter and total hospital costs were less in the reservoir group than in the conventional chemotherapy group (p < 0.05 and p < 0.01, respectively). Transcatheter arterial chemotherapy using implanted reservoirs can be carried out on a day-care basis and may be beneficial for the treatment of patients with advanced hepatocellular carcinoma.